Super-charging drug development for COVID-19

April 13, 2020

Researchers are ramping up production of a promising drug that has proven effective in obliterating SARS-CoV in cellular cultures. The team hopes that the drug might also be effective in the fight against SARS's close genetic cousin, the novel coronavirus (COVID-19).

Led by Northwestern University and ShanghaiTech University, the team has produced the promising molecule, called valinomycin, in a cell-free system. With this approach, they increased production yields more than 5,000 times in just a few rapid design cycles, achieving higher concentrations of the molecule than achieved previously in cells.

"Because we use cell-free systems, we can optimize production faster than in cells to further increase yields," said Northwestern's Michael Jewett, who co-led the study. "For example, pathway optimization cycles take days rather than weeks or months, and this speed could be ever so important when dealing with a pandemic like the coronavirus COVID-19 outbreak."

The research was published online recently in the journal Metabolic Engineering and will appear in the July 2020 print issue.

Jewett is the Walter P. Murphy Professor of Chemical and Biological Engineering in the McCormick School of Engineering and director of Northwestern's Center for Synthetic Biology. He co-led the work with Jian Li, an assistant professor in the School of Physical Science and Technology at ShanghaiTech.

Jewett leads multiple projects that use cell-free biotechnology to accelerate COVID-19 therapeutics. His group takes the molecular machinery out of cells, and then uses that machinery to make a product, such as therapeutics, in a safe, inexpensive and rapid manner. The idea is akin to opening the hood of a car and removing the engine, which allows researchers to use the engine for different purposes, free from the constraints of the car.

A naturally occurring peptide, valinomycin has recently emerged as a potential antiviral to treat SARS. Jewett imagines using cell-free synthetic biology to find similar molecules or to modify valinomycin to make it safer and more potent.
-end-
Jewett is a member of Northwestern's Chemistry of Life Processes Institute and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

The research, "Total in vitro biosynthesis of the nonribosomal macrolactone peptide valinomycin," was supported by the National Institutes of Health (award number 1U19AI142780-01), the David and Lucile Packard Foundation, the Camille Dreyfus Teacher-Scholar Program, the National Natural Science Foundation of China (award numbers 31971348 and 31800720), the National Natural Science Foundation of Shanghai (award number 19ZR1477200), and the Shanghai Pujiang Program (award number 18PJ1408000).

Northwestern University

Related Synthetic Biology Articles from Brightsurf:

Deep learning takes on synthetic biology
Machine learning is helping biologists solve hard problems, including designing effective synthetic biology tools.

Machine learning takes on synthetic biology: algorithms can bioengineer cells for you
Scientists at Lawrence Berkeley National Laboratory have developed a new tool that adapts machine learning algorithms to the needs of synthetic biology to guide development systematically.

Cell-free synthetic biology comes of age
In a review paper published in Nature Reviews Genetics, Professor Michael Jewett explores how cell-free gene expression stands to help the field of synthetic biology dramatically impact society, from the environment to medicine to education.

Scientists develop electrochemical platform for cell-free synthetic biology
Scientists at the University of Toronto (U of T) and Arizona State University (ASU) have developed the first direct gene circuit to electrode interface by combining cell-free synthetic biology with state-of-the-art nanostructured electrodes.

Gene-OFF switches tool up synthetic biology
Wyss researchers and their colloaborators have developed two types of programmable repressor elements that can switch off the production of an output protein in synthetic biology circuits by up to 300-fold in response to almost any triggering nucleotide sequence.

Tennessee researchers join call for responsible development of synthetic biology
Engineering biology is transforming technology and science. Researchers in the international Genome Project-write, including two authors from the UTIA Center for Agricultural Synthetic Biology, outline the technological advances needed to secure a safe, responsible future in the Oct.

Scientists chart course toward a new world of synthetic biology
A UC Berkeley team with NSF funding has compiled a roadmap for the future of synthetic or engineering biology, based on the input of 80 leaders in the field from more than 30 institutions.

DFG presents position paper on synthetic biology
Clear distinction between synthetic biology and underlying methods required / No new potential risks associated with current research work

Commandeering microbes pave way for synthetic biology in military environments
A team of scientists from the US Army Research Laboratory and the Massachusetts Institute of Technology have developed and demonstrated a pioneering synthetic biology tool to deliver DNA programming into a broad range of bacteria.

BioBits: Teaching synthetic biology to K-12 students
As biologists have probed deeper into the genetic underpinnings of life, K-12 schools have struggled to provide a curriculum that reflects those advances.

Read More: Synthetic Biology News and Synthetic Biology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.